Cutler Group’s Indaptus Therapeutics INDP Stock Holding History

Cutler Group’s Portfolio INDP Stock Details INDP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1	Closed	–	–	5693
2021 Q3	$0	Hold	1	–	–	﹤0.01%	5999
2021 Q2	$0	Hold	1	–	–	﹤0.01%	6000
2021 Q1	$0	Hold	1	–	–	﹤0.01%	5940
2020 Q4	$0	Hold	1	–	–	﹤0.01%	5117
2020 Q3	$0	Hold	1	–	–	﹤0.01%	4948
2020 Q2	$0	Hold	1	–	–	﹤0.01%	4607
2020 Q1	$0	Hold	1	–	–	﹤0.01%	4318
2019 Q4	$1K	Hold	1	–	–	﹤0.01%	3692
2019 Q3	$1K	Hold	1	–	–	﹤0.01%	3736
2019 Q2	$11K	Hold	1	–	–	﹤0.01%	2615
2019 Q1	$20K	Buy	+1	New	+$17.5K	﹤0.01%	2049

Other funds holding INDP

SWP

Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

IHL

Investment House LLC Redondo Beach, California $1.92B AUM 25.81% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

UCFA

United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return

Cutler Group's INDP Position: Q4 2021 in Review

Cutler Group sold out of Indaptus Therapeutics (INDP) in Q4 2021, closing a stake of 1 share.

Cutler Group first reported a position in INDP in Q1 2019 and held it in 11 quarters. The position peaked at $20K in Q1 2019. 14 funds tracked by Wall St. Rank hold INDP as of Q4 2021.

Cutler Group reported no remaining Indaptus Therapeutics position as of Q4 2021 after selling out during the quarter.
Cutler Group sold 1 Indaptus Therapeutics share in Q4 2021.
Cutler Group first reported a position in Indaptus Therapeutics in Q1 2019 and held it in 11 quarters.
Cutler Group's Indaptus Therapeutics position peaked at $20K in Q1 2019.
14 funds tracked by Wall St. Rank held Indaptus Therapeutics as of Q4 2021.

Based on Cutler Group's 13F filing for Q4 2021, filed 18 Jan 2022.